You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrimethaphan
Accession NumberDB01116  (APRD00044)
TypeSmall Molecule
GroupsApproved
DescriptionA nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery. [PubChem]
Structure
Thumb
Synonyms
Thimethaphan
Trimetaphan
Trimetaphanum
Trimethaphan
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArfonadNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Trimethaphan camsylate
ThumbNot applicableDBSALT001381
Categories
UNII6G8X656T45
CAS number7187-66-8
WeightAverage: 365.512
Monoisotopic: 365.168759122
Chemical FormulaC22H25N2OS
InChI KeyInChIKey=CHQOEHPMXSHGCL-UHFFFAOYSA-N
InChI
InChI=1S/C22H25N2OS/c25-22-23(14-17-8-3-1-4-9-17)19-16-26-13-7-12-20(26)21(19)24(22)15-18-10-5-2-6-11-18/h1-6,8-11,19-21H,7,12-16H2/q+1
IUPAC Name
3,5-dibenzyl-4-oxo-8λ⁴-thia-3,5-diazatricyclo[6.3.0.0²,⁶]undecan-8-ylium
SMILES
O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as thienoimidazolidines. These are heterocyclic compounds containing a thiophene ring fused to an imidazolidine ring. Thiophene is 5-membered ring consisting of four carbon atoms and one sulfur atom. Imidazolidine is 5-membered saturated ring of three carbon atoms, and two nitrogen centers at the 1- and 3-positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassThienoimidazolidines
Sub ClassNot Available
Direct ParentThienoimidazolidines
Alternative Parents
Substituents
  • Thienoimidazolidine
  • Phenylmethylamine
  • Benzylamine
  • Benzenoid
  • Imidazolidinone
  • Monocyclic benzene moiety
  • Thiophene
  • Imidazolidine
  • Urea
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Organic cation
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the controlled reduction of blood pressure during surgery and in the treatment of hypertensive emergencies.
PharmacodynamicsTrimethaphan is indicated for production of controlled hypotension during surgery to reduce bleeding into the surgical field and also for rapid reduction of blood pressure in the treatment of hypertensive emergencies, especially in patients with acute dissecting aneurysm, and in the emergency treatment of pulmonary edema in patients with pulmonary hypertension associated with systemic hypertension.
Mechanism of actionTrimethaphan is a ganglionic blocking agent prevents stimulation of postsynaptic receptors by competing with acetylcholine for these receptor sites. Additional effects may include direct peripheral vasodilation and release of histamine. Trimethaphan's hypotensive effect is due to reduction in sympathetic tone and vasodilation, and is primarily postural.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9641
Blood Brain Barrier+0.9897
Caco-2 permeable-0.5053
P-glycoprotein substrateSubstrate0.6942
P-glycoprotein inhibitor IInhibitor0.6012
P-glycoprotein inhibitor IINon-inhibitor0.6356
Renal organic cation transporterInhibitor0.6812
CYP450 2C9 substrateNon-substrate0.7161
CYP450 2D6 substrateNon-substrate0.6162
CYP450 3A4 substrateNon-substrate0.5152
CYP450 1A2 substrateNon-inhibitor0.5223
CYP450 2C9 inhibitorInhibitor0.5
CYP450 2D6 inhibitorInhibitor0.5134
CYP450 2C19 inhibitorInhibitor0.7361
CYP450 3A4 inhibitorNon-inhibitor0.8947
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.847
Ames testNon AMES toxic0.6511
CarcinogenicityNon-carcinogens0.9545
BiodegradationNot ready biodegradable0.9606
Rat acute toxicity2.3658 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.597
hERG inhibition (predictor II)Inhibitor0.7575
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.473Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00665 mg/mLALOGPS
logP4.4ALOGPS
logP2.32ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)-2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area23.55 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity105.43 m3·mol-1ChemAxon
Polarizability40.13 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC02BA01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with 1,10-Phenanthroline.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Trimethaphan.
AcebutololTrimethaphan may increase the hypotensive activities of Acebutolol.
AclidiniumAclidinium may increase the anticholinergic activities of Trimethaphan.
AclidiniumThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Aclidinium.
AlfentanilThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the hypotensive activities of Trimethaphan.
AliskirenTrimethaphan may increase the hypotensive activities of Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Alphacetylmethadol.
AlprenololAlprenolol may increase the hypotensive activities of Trimethaphan.
AmbenoniumThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Ambenonium.
AmbrisentanTrimethaphan may increase the hypotensive activities of Ambrisentan.
AmifostineTrimethaphan may increase the hypotensive activities of Amifostine.
AmlodipineAmlodipine may increase the hypotensive activities of Trimethaphan.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Trimethaphan.
AtenololAtenolol may increase the hypotensive activities of Trimethaphan.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Trimethaphan.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Trimethaphan.
BenactyzineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Benactyzine.
BenazeprilBenazepril may increase the hypotensive activities of Trimethaphan.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Trimethaphan.
BenmoxinBenmoxin may increase the hypotensive activities of Trimethaphan.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Trimethaphan.
BepridilTrimethaphan may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Trimethaphan.
BethanidineBethanidine may increase the hypotensive activities of Trimethaphan.
BezitramideThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Bezitramide.
BimatoprostBimatoprost may increase the hypotensive activities of Trimethaphan.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Trimethaphan.
BisoprololBisoprolol may increase the hypotensive activities of Trimethaphan.
BosentanBosentan may increase the hypotensive activities of Trimethaphan.
Botulinum Toxin Type ATrimethaphan may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BTrimethaphan may increase the anticholinergic activities of Botulinum Toxin Type B.
BretyliumTrimethaphan may increase the hypotensive activities of Bretylium.
BrimonidineTrimethaphan may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Trimethaphan.
BupranololTrimethaphan may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Buprenorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Butorphanol.
CandesartanCandesartan may increase the hypotensive activities of Trimethaphan.
CandoxatrilCandoxatril may increase the hypotensive activities of Trimethaphan.
CaptoprilTrimethaphan may increase the hypotensive activities of Captopril.
CarfentanilThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Carfentanil.
CaroxazoneCaroxazone may increase the hypotensive activities of Trimethaphan.
CarteololCarteolol may increase the hypotensive activities of Trimethaphan.
CarvedilolTrimethaphan may increase the hypotensive activities of Carvedilol.
CeliprololTrimethaphan may increase the hypotensive activities of Celiprolol.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Trimethaphan.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Chlorphenoxamine.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Trimethaphan.
CilazaprilTrimethaphan may increase the hypotensive activities of Cilazapril.
CimetropiumTrimethaphan may increase the anticholinergic activities of Cimetropium.
ClonidineClonidine may increase the hypotensive activities of Trimethaphan.
CodeineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Codeine.
CoumaphosThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Coumaphos.
CryptenamineCryptenamine may increase the hypotensive activities of Trimethaphan.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Trimethaphan.
CyclothiazideCyclothiazide may increase the hypotensive activities of Trimethaphan.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Trimethaphan.
DebrisoquinTrimethaphan may increase the hypotensive activities of Debrisoquin.
DecamethoniumThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Decamethonium.
DemecariumThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Demecarium.
DeserpidineTrimethaphan may increase the hypotensive activities of Deserpidine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Trimethaphan.
DexetimideThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dexetimide.
DextromoramideThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dezocine.
DiazoxideDiazoxide may increase the hypotensive activities of Trimethaphan.
DichlorvosThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Trimethaphan.
DihydrocodeineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dihydromorphine.
DiltiazemDiltiazem may increase the hypotensive activities of Trimethaphan.
DiphenoxylateThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Diphenoxylate.
DonepezilThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Donepezil.
DorzolamideDorzolamide may increase the hypotensive activities of Trimethaphan.
DoxazosinDoxazosin may increase the hypotensive activities of Trimethaphan.
DPDPEThe risk or severity of adverse effects can be increased when Trimethaphan is combined with DPDPE.
DronabinolTrimethaphan may increase the tachycardic activities of Dronabinol.
EchothiophateThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Edrophonium.
EfonidipineTrimethaphan may increase the hypotensive activities of Efonidipine.
EluxadolineTrimethaphan may increase the constipating activities of Eluxadoline.
EnalaprilEnalapril may increase the hypotensive activities of Trimethaphan.
EnalaprilatTrimethaphan may increase the hypotensive activities of Enalaprilat.
EpoprostenolTrimethaphan may increase the hypotensive activities of Epoprostenol.
EprosartanEprosartan may increase the hypotensive activities of Trimethaphan.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Trimethaphan.
EthylmorphineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Ethylmorphine.
EtorphineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Etorphine.
FelodipineFelodipine may increase the hypotensive activities of Trimethaphan.
FenoldopamFenoldopam may increase the hypotensive activities of Trimethaphan.
FentanylThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Fentanyl.
FenthionThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Fenthion.
FesoterodineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Fesoterodine.
FosinoprilFosinopril may increase the hypotensive activities of Trimethaphan.
FurazolidoneFurazolidone may increase the hypotensive activities of Trimethaphan.
GalantamineThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Trimethaphan.
Ginkgo bilobaThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Trimethaphan.
GlycopyrroniumTrimethaphan may increase the anticholinergic activities of Glycopyrronium.
GuanabenzGuanabenz may increase the hypotensive activities of Trimethaphan.
GuanadrelGuanadrel may increase the hypotensive activities of Trimethaphan.
GuanethidineTrimethaphan may increase the hypotensive activities of Guanethidine.
GuanfacineGuanfacine may increase the hypotensive activities of Trimethaphan.
HeroinThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Heroin.
HexamethoniumTrimethaphan may increase the hypotensive activities of Hexamethonium.
HomatropineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Huperzine A.
HydracarbazineHydracarbazine may increase the hypotensive activities of Trimethaphan.
HydralazineTrimethaphan may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Trimethaphan.
HydrocodoneThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Hydrocodone.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Trimethaphan.
HydromorphoneThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Hydromorphone.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Trimethaphan.
IloprostIloprost may increase the hypotensive activities of Trimethaphan.
IndapamideIndapamide may increase the hypotensive activities of Trimethaphan.
IndenololTrimethaphan may increase the hypotensive activities of Indenolol.
IndoraminTrimethaphan may increase the hypotensive activities of Indoramin.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Trimethaphan.
IproclozideIproclozide may increase the hypotensive activities of Trimethaphan.
IproniazidIproniazid may increase the hypotensive activities of Trimethaphan.
IrbesartanIrbesartan may increase the hypotensive activities of Trimethaphan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Trimethaphan.
IsoflurophateThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Isoflurophate.
IsradipineIsradipine may increase the hypotensive activities of Trimethaphan.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Trimethaphan.
KetobemidoneThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Ketobemidone.
LabetalolLabetalol may increase the hypotensive activities of Trimethaphan.
LacidipineTrimethaphan may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Trimethaphan.
LercanidipineLercanidipine may increase the hypotensive activities of Trimethaphan.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Levorphanol.
LisinoprilLisinopril may increase the hypotensive activities of Trimethaphan.
LofentanilThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Lofentanil.
LofexidineTrimethaphan may increase the hypotensive activities of Lofexidine.
LosartanLosartan may increase the hypotensive activities of Trimethaphan.
MacitentanTrimethaphan may increase the hypotensive activities of Macitentan.
MalathionThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Malathion.
ManidipineTrimethaphan may increase the hypotensive activities of Manidipine.
MebanazineMebanazine may increase the hypotensive activities of Trimethaphan.
MecamylamineMecamylamine may increase the hypotensive activities of Trimethaphan.
MefloquineThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Mefloquine.
MemantineThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Memantine.
MethadoneThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Trimethaphan.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Trimethaphan.
MethyldopaMethyldopa may increase the hypotensive activities of Trimethaphan.
Methylene blueMethylene blue may increase the hypotensive activities of Trimethaphan.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Trimethaphan.
MetipranololTrimethaphan may increase the hypotensive activities of Metipranolol.
MetixeneThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Metixene.
MetolazoneMetolazone may increase the hypotensive activities of Trimethaphan.
MetoprololMetoprolol may increase the hypotensive activities of Trimethaphan.
MianserinMianserin may increase the anticholinergic activities of Trimethaphan.
MibefradilTrimethaphan may increase the hypotensive activities of Mibefradil.
MinaprineThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Minaprine.
MinoxidilMinoxidil may increase the hypotensive activities of Trimethaphan.
MirabegronThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Mirabegron.
MoclobemideMoclobemide may increase the hypotensive activities of Trimethaphan.
MoexiprilMoexipril may increase the hypotensive activities of Trimethaphan.
MolsidomineMolsidomine may increase the hypotensive activities of Trimethaphan.
MorphineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Morphine.
MoxonidineTrimethaphan may increase the hypotensive activities of Moxonidine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Trimethaphan is combined with N-butylscopolammonium bromide.
NabiloneTrimethaphan may increase the tachycardic activities of Nabilone.
NadololTrimethaphan may increase the hypotensive activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Nalbuphine.
NebivololTrimethaphan may increase the hypotensive activities of Nebivolol.
NeostigmineThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Neostigmine.
NialamideNialamide may increase the hypotensive activities of Trimethaphan.
NicardipineNicardipine may increase the hypotensive activities of Trimethaphan.
NicorandilTrimethaphan may increase the hypotensive activities of Nicorandil.
NiguldipineTrimethaphan may increase the hypotensive activities of Niguldipine.
NilvadipineTrimethaphan may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Trimethaphan.
NisoldipineNisoldipine may increase the hypotensive activities of Trimethaphan.
NitrendipineNitrendipine may increase the hypotensive activities of Trimethaphan.
NitroprussideNitroprusside may increase the hypotensive activities of Trimethaphan.
NormethadoneThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Normethadone.
NVA237The risk or severity of adverse effects can be increased when Trimethaphan is combined with NVA237.
ObinutuzumabTrimethaphan may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Trimethaphan.
OlmesartanOlmesartan may increase the hypotensive activities of Trimethaphan.
OmapatrilatOmapatrilat may increase the hypotensive activities of Trimethaphan.
OpiumThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Orphenadrine.
OxprenololTrimethaphan may increase the hypotensive activities of Oxprenolol.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Trimethaphan.
OxycodoneThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Trimethaphan.
PancuroniumThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Pancuronium.
PargylineTrimethaphan may increase the hypotensive activities of Pargyline.
PenbutololTrimethaphan may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Pentazocine.
PentoliniumPentolinium may increase the hypotensive activities of Trimethaphan.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Trimethaphan.
PerindoprilPerindopril may increase the hypotensive activities of Trimethaphan.
PethidineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Pethidine.
PhenelzinePhenelzine may increase the hypotensive activities of Trimethaphan.
PheniprazinePheniprazine may increase the hypotensive activities of Trimethaphan.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Trimethaphan.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Trimethaphan.
PhentolaminePhentolamine may increase the hypotensive activities of Trimethaphan.
PhysostigmineThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Physostigmine.
PinacidilTrimethaphan may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Trimethaphan.
PipecuroniumThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Pipecuronium.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Trimethaphan.
PirlindolePirlindole may increase the hypotensive activities of Trimethaphan.
PivhydrazinePivhydrazine may increase the hypotensive activities of Trimethaphan.
PolythiazideTrimethaphan may increase the hypotensive activities of Polythiazide.
Potassium ChlorideTrimethaphan may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Trimethaphan.
PrazosinPrazosin may increase the hypotensive activities of Trimethaphan.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Trimethaphan.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Trimethaphan.
PropranololPropranolol may increase the hypotensive activities of Trimethaphan.
PyridostigmineThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Pyridostigmine.
QuinaprilQuinapril may increase the hypotensive activities of Trimethaphan.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Trimethaphan.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Trimethaphan.
QuinineQuinine may increase the hypotensive activities of Trimethaphan.
RamiprilRamipril may increase the hypotensive activities of Trimethaphan.
RamosetronTrimethaphan may increase the constipating activities of Ramosetron.
RasagilineRasagiline may increase the hypotensive activities of Trimethaphan.
RemifentanilThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Remifentanil.
RemikirenRemikiren may increase the hypotensive activities of Trimethaphan.
RescinnamineTrimethaphan may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Trimethaphan.
RiociguatTrimethaphan may increase the hypotensive activities of Riociguat.
RituximabTrimethaphan may increase the hypotensive activities of Rituximab.
RivastigmineThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Rivastigmine.
SafrazineSafrazine may increase the hypotensive activities of Trimethaphan.
SaprisartanTrimethaphan may increase the hypotensive activities of Saprisartan.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trimethaphan.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Scopolamine butylbromide.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Trimethaphan.
SelegilineSelegiline may increase the hypotensive activities of Trimethaphan.
SelexipagTrimethaphan may increase the hypotensive activities of Selexipag.
SildenafilSildenafil may increase the antihypertensive activities of Trimethaphan.
SitaxentanTrimethaphan may increase the hypotensive activities of Sitaxentan.
SolifenacinThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Solifenacin.
SpiraprilTrimethaphan may increase the hypotensive activities of Spirapril.
SufentanilThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Sufentanil.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Trimethaphan.
TacrineThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Tacrine.
TadalafilTadalafil may increase the antihypertensive activities of Trimethaphan.
TapentadolThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Tapentadol.
TelmisartanTelmisartan may increase the hypotensive activities of Trimethaphan.
TemocaprilTrimethaphan may increase the hypotensive activities of Temocapril.
TerlipressinTrimethaphan may increase the hypotensive activities of Terlipressin.
TiboloneTrimethaphan may increase the hypotensive activities of Tibolone.
TicrynafenTrimethaphan may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Trimethaphan.
TiotropiumTrimethaphan may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Trimethaphan.
TolazolineTolazoline may increase the hypotensive activities of Trimethaphan.
ToloxatoneToloxatone may increase the hypotensive activities of Trimethaphan.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Trimethaphan.
TopiramateThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Topiramate.
TorasemideTorasemide may increase the hypotensive activities of Trimethaphan.
TramadolThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Tramadol.
TrandolaprilTrandolapril may increase the hypotensive activities of Trimethaphan.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Trimethaphan.
TranylcypromineTranylcypromine may increase the hypotensive activities of Trimethaphan.
TravoprostTravoprost may increase the hypotensive activities of Trimethaphan.
TreprostinilTreprostinil may increase the hypotensive activities of Trimethaphan.
TrichlorfonThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Trichlorfon.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Trimethaphan.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Trimethaphan.
TrimazosinTrimethaphan may increase the hypotensive activities of Trimazosin.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Trimethaphan.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Trimethaphan.
TubocurarineThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Tubocurarine.
UdenafilUdenafil may increase the antihypertensive activities of Trimethaphan.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Trimethaphan.
UmeclidiniumThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Umeclidinium.
UnoprostoneTrimethaphan may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Trimethaphan.
VardenafilVardenafil may increase the antihypertensive activities of Trimethaphan.
VecuroniumThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Vecuronium.
XylometazolineTrimethaphan may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Trimethaphan.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor binding
Specific Function:
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes t...
Gene Name:
CHRNA10
Uniprot ID:
Q9GZZ6
Molecular Weight:
49704.295 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kurenny DE, Selyanko AA, Derkach VA, Gmiro VE, Skok VI: Mechanism of long-lasting block of ganglion nicotinic receptors by mono-ammonium compounds with long aliphatic chain. J Auton Nerv Syst. 1994 Aug;48(3):231-40. [PubMed:7963258 ]
  4. Loiacono R, Stephenson J, Stevenson J, Mitchelson F: Multiple binding sites for nicotine receptor antagonists in inhibiting [3H](-)-nicotine binding in rat cortex. Neuropharmacology. 1993 Sep;32(9):847-53. [PubMed:8232788 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Nakamura K, Koide M, Imanaga T, Ogasawara H, Takahashi M, Yoshikawa M: Prolonged neuromuscular blockade following trimetaphan infusion. A case report and in vitro study of cholinesterase inhibition. Anaesthesia. 1980 Dec;35(12):1202-7. [PubMed:7457791 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23